Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)

An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal Choroidal Neovascularization Due to Exudative Age-Related Macular Degeneration.

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00051129

Enrollment

291

Registered

2003-01-07

Start date

2007-01-31

Completion date

2008-05-31

Last updated

2012-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-Related Maculopathies, Age-Related Maculopathy, Macular Degeneration, Maculopathies, Age-Related, Maculopathy, Age-Related

Keywords

AMD, anecortave acetate, wet AMD, age-related macular degeneration, Macular Degeneration, Maculopathy, Age-Related, Age-Related Maculopathies, Age-Related Maculopathy, Maculopathies, Age-Related

Brief summary

The purpose of this study was to evaluate anecortave acetate compared to placebo for maintenance of visual acuity after 24 months of treatment in patients with subfovial choroidal neovascularization (CNV) due to exudative age-related macular degeneration (AMD).

Interventions

DRUGAnecortave Acetate 15 mg sterile suspension

0.5 ml of 30 mg/ml administered as a posterior juxtascleral injection

OTHERAnecortave Acetate Vehicle

Administered as a posterior juxtascleral injection

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of exudative AMD and a primary or recurrent subfoveal CNV lesion in the study eye. * Other protocol-defined inclusion criteria may apply.

Exclusion criteria

* Under 50 years. * Other protocol-defined

Design outcomes

Primary

Measure	Time frame
Mean change from baseline in logMAR visual acuity score at 12 months	Month 12

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026